ArticleDiscover oncology2026
Pan-cancer analysis and experimental validation identify CYP19A1 as a prognostic biomarker and oncogenic driver associated with tumor immune microenvironment regulation in gastrointestinal cancers.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCYP19A1, which encodes the enzyme aromatase necessary for estrogen production, is known to be involved in hormone-sensitive cancers, but its role in gastrointestinal cancers is not completely clear.
methodsTo examine CYP19A1 in gastrointestinal cancers, we carried out pan-cancer bioinformatics analyses using the TCGA dataset as the main source, combined with experimental validations. A systematic analysis was conducted on transcriptomic, clinical, epigenetic, immune infiltration data, functional networks, and regulatory mechanisms. Functional experiments were conducted using mouse models of gastric and colon cancer, as well as human cancer cell lines such as AGS, MKN45, SGC7901, HCT116, SW480, and LoVo.
resultsHigher levels of CYP19A1 expression are found in stomach, liver, and colon cancers, which are associated with more advanced stages and poorer prognosis. The increase in its expression may be related to immune profiles specific to certain cancer types and might help create an immunosuppressive tumor microenvironment in gastrointestinal cancers, as shown by immune infiltration analysis. GO and KEGG enrichment analyses suggest that CYP19A1 is linked to pathways involved in steroid hormone synthesis, cancer-related signaling, and endocrine resistance, indicating its role in the progression of hormone-driven cancers. Functional tests indicated that higher CYP19A1 expression enhanced cancer cell migration and invasion, whereas lowering it produced the opposite outcome.
conclusionsThe combined computational and experimental findings identify CYP19A1 as a prognostic biomarker and a functional contributor to gastrointestinal cancers. The results support exploring CYP19A1-specific treatments, including aromatase inhibitors and immune-modulating tactics, in this cancer group with a considerable burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.